ArticleClinical and experimental medicine2026
Bioinformatics and experimental approaches identify NME8 as a promoter of the metastasis of renal cell carcinoma by activating the JAK/STAT signaling pathway.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Functional Diversity and Emerging Roles of Human NME/NDPK Group II Proteins.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Renal cell carcinoma (RCC) presents treatment challenges in advanced stages owing to its metastatic potential. This study explored the role of NME8, a nucleotide metabolism-related protein, in the metastasis and prognosis of RCC. Analysis of the GSE66272 dataset and of The Cancer Genome Atlas (TCGA) specimens revealed that NME8 is overexpressed in renal cancer and is correlated with poor patient outcomes, as determined by Cox regression. Functional assessments, including Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses and immune infiltration studies, were conducted. In vitro experiments involving the creation of stable NME8-knockdown cell lines revealed that NME8 knockdown significantly reduced renal cancer cell proliferation, migration, and invasion while increasing apoptosis. Immunoblotting indicated that NME8 was associated with epithelial-mesenchymal transition (EMT) proteins such as E-cadherin, vimentin, and Twist. Furthermore, exposure to the Janus kinase (JAK) inhibitor ruxolitinib and the signal transducer and activator of transcription (STAT)3 inhibitor stattic demonstrated that NME8 promoted RCC metastasis by activating the JAK/STAT signaling pathway. Elevated NME8 levels were linked to immune cell infiltration. In conclusion, our findings suggest that NME8 contributes to RCC metastasis by promoting JAK/STAT-mediated EMT and modulating the tumor immune microenvironment. While elevated NME8 expression correlates with poor prognosis in public cohorts, its utility as a clinical prognostic biomarker requires further validation in independent patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.